Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AJITA NARAYAN

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1467663856
CMS profile
66731
Location
LAFAYETTE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$18.48

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $18.48 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $18.48 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AJITA NARAYAN

NPI 1467663856 · CMS profile ID 66731

Allopathic & Osteopathic Physicians / Internal Medicine

LAFAYETTE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467663856?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AJITA NARAYAN, NPI 1467663856, CMS profile ID 66731. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467663856?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). AJITA NARAYAN, NPI 1467663856, CMS profile ID 66731. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467663856?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
AJITA NARAYAN, NPI 1467663856, CMS profile ID 66731, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1467663856?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $18.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $18.4803/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105099733 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $436.46 24
PY2020 $71.41 3
PY2021 $62.86 2
PY2022 $49.05 2
PY2024 $18.48 1
PY2025 $317.87 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $22,767.13 1
PY2023 Principal investigator $116,183.12 3
PY2022 Principal investigator $220,933.10 26
PY2021 Principal investigator $590,612.06 36

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 2 Merck Sharp & Dohme Corporation $221,981.05 12/31/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma No dispute reported 06/30/2026 848752783
Principal investigator 1 ABBVIE INC. $96.60 12/02/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792484861
Principal investigator 1 ABBVIE INC. $8,184.08 12/02/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792484863
Principal investigator 1 ABBVIE INC. $15,724.16 12/02/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792484865
Principal investigator 1 ABBVIE INC. $5,178.88 12/02/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792484867
Principal investigator 1 ABBVIE INC. $776.88 12/02/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792484869
Principal investigator 1 ABBVIE INC. $88.88 12/02/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792484871
Principal investigator 1 ABBVIE INC. $4,352.00 12/02/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792484873
Principal investigator 1 ABBVIE INC. $35.62 12/02/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792484875
Principal investigator 1 ABBVIE INC. $6,124.81 12/02/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792484877
Principal investigator 1 ABBVIE INC. $14,121.66 12/02/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792484879
Principal investigator 1 ABBVIE INC. $3,582.20 12/02/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792484881
Principal investigator 1 ABBVIE INC. $5,016.24 12/02/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792484883
Principal investigator 1 ABBVIE INC. $31.00 12/02/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792484885
Principal investigator 1 Genentech, Inc. $6,671.00 11/26/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY CENTER/THE CARE GROUP
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 835963225
Principal investigator 1 Genentech, Inc. $857.50 11/24/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY CENTER/THE CARE GROUP
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 835963221
Principal investigator 1 Genentech, Inc. $12,611.00 11/15/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY CENTER/THE CARE GROUP
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 835963217
Principal investigator 1 ABBVIE INC. $526.88 11/12/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792482715
Principal investigator 1 Merck Sharp & Dohme Corporation $59,500.00 11/08/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY CENTER
An Open Label, First in Human FIH, Phase 1 Trial of LVGN6051 as Single Agent and in Combination with Anti-PD-1 Antibody in Advanced or Metastatic Malignancy No dispute reported 06/30/2026 848739773
Principal investigator 1 PFIZER INC. $1,748.75 11/05/2021 Non-covered Recipient Entity
Horizon Oncology Research LLC
A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES AND TREATMENT INTENSIFICATION OF A VACCINEBASED IMMUNOTHERAPY REGIMEN2 VBIR2 PF06936308 FOR ADVANCED NONSMALL CELL LUNG CANCER AND METASTATIC TRIPLENEGATIVE BREAST CANCER No dispute reported 06/30/2026 832881387
Principal investigator 1 ABBVIE INC. $653.28 11/04/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792481209
Principal investigator 1 Genentech, Inc. $2,880.00 11/03/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY CENTER/THE CARE GROUP
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 835963211
Principal investigator 1 Genentech, Inc. $8,003.00 10/27/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY CENTER/THE CARE GROUP
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 835963207
Principal investigator 1 Genentech, Inc. $138.88 10/22/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY CENTER/THE CARE GROUP
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 835963201
Principal investigator 1 ABBVIE INC. $282.88 10/21/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792480125
Principal investigator 1 ABBVIE INC. $150.00 10/18/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792479955
Principal investigator 1 ABBVIE INC. $2,487.20 10/18/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792479957
Principal investigator 1 Genentech, Inc. $8,287.00 10/11/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY CENTER/THE CARE GROUP
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 835963191
Principal investigator 1 Genentech, Inc. $202.62 10/11/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY CENTER/THE CARE GROUP
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 835963195
Principal investigator 1 ABBVIE INC. $5,037.76 09/20/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792475925
Principal investigator 1 ABBVIE INC. $96.60 09/20/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792475927
Principal investigator 1 Genentech, Inc. $10.96 09/20/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY CENTER/THE CARE GROUP
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 835963185
Principal investigator 1 Genentech, Inc. $192.59 09/15/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY CENTER/THE CARE GROUP
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 835963179
Principal investigator 1 Genentech, Inc. $9,500.00 09/13/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY CENTER/THE CARE GROUP
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 835963173
Principal investigator 1 ABBVIE INC. $120,680.10 09/09/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. No dispute reported 06/30/2026 792474731
Principal investigator 1 Merck Sharp & Dohme Corporation $64,800.00 07/29/2021 Non-covered Recipient Entity
HORIZON ONCOLOGY RESEARCH LLC
A Phase 1 Study of TJ011133 Administered Alone or in Combination with Pembrolizumab or Rituximab in Subjects with Relapsed,Refractory Advanced Solid Tumors and Lymphoma No dispute reported 06/30/2026 848739741